Editorial: Opportunistic infections due to Aspergillus.
D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000209:etiology* / Q000628:therapy; D003428:Cross Infection / Q000209:etiology; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications; D007165:Immunosuppression Therapy / Q000009:adverse effects; D008172:Lung Diseases, Fungal / Q000628:therapy; D011013:Pneumonectomy
D000935:Antifungal Agents